title: [Antidotes for the new oral anticoagulants: Reality and expectations].
authors.affiliation: División de Farmacología y Evaluación Clínica, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, España. Electronic address: agomezo@aemps.es.
authors.forename: Antonio
authors.initials: A
authors.lastname: Gómez-Outes
authors.affiliation: Servicio de Hematología, Clínica Universidad de Navarra, Pamplona, Navarra, España.
authors.forename: Ramón
authors.initials: R
authors.lastname: Lecumberri
mesh_terms: D000284:Administration, Oral; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000925:Anticoagulants / Q000009:adverse effects*; D001120:Arginine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003029:Coagulants / Q000627:therapeutic use*; D015951:Factor Xa / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced* / Q000188:drug therapy*; D006801:Humans; D010879:Piperazines / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D003029:Coagulants; C580915:PRT064445; D010879:Piperazines; D011994:Recombinant Proteins; D001120:Arginine; C000594745:idarucizumab; D015951:Factor Xa; C000593571:PER977